Celator Pharmaceuticals (Canada)

Recent papers from Celator Pharmaceuticals (Canada)

1. Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogensJournal of Applied Microbiology · 2026
2. Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomesJournal of drug targeting · 2016
3. Efficacy of CPX‐351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramPediatric Blood & Cancer · 2014
4. Nanoscale Particulate Systems for Multidrug Delivery: Towards Improved Combination ChemotherapyTherapeutic Delivery · 2014
5. Structure–activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitorsBioorganic & Medicinal Chemistry Letters · 2012
6. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndromeProceedings of the National Academy of Sciences · 2011
7. A novel slow-inactivation-specific ion channel modulator attenuates neuropathic painPain · 2011
8. Optimizing Liposomal Cisplatin Efficacy through Membrane Composition ManipulationsChemotherapy Research and Practice · 2011
9. Identification of Sodium Channel Isoforms That Mediate Action Potential Firing in Lamina I/II Spinal Cord NeuronsMolecular Pain · 2011
10. Use of nanoscale delivery systems to maintain synergistic drug ratiosin vivoExpert Opinion on Drug Delivery · 2010
11. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenograftsLeukemia & lymphoma/Leukemia and lymphoma · 2010
12. Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivoMolecular Cancer Therapeutics · 2009
13. A Fluorescence-Based High-Throughput Screening Assay for the Identification of T-Type Calcium Channel BlockersAssay and Drug Development Technologies · 2009
14. Optimizing Combination Chemotherapy by Controlling Drug RatiosMolecular Interventions · 2007
15. Increased Preclinical Efficacy of Irinotecan and Floxuridine Coencapsulated Inside Liposomes Is Associated With Tumor Delivery of Synergistic Drug RatiosOncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2006
16. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing miceMolecular Cancer Therapeutics · 2006
17. Combining doxorubicin and liposomal anti‐HER‐2/NEU antisense oligodeoxynucleotides to treat HER‐2/NEU‐expressing MDA‐MB‐435 breast tumor modelJournal of Experimental Therapeutics and Oncology · 2003
18. Poster AbstractsJournal of Liposome Research · 2003
19. Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol)Bioscience Reports · 2002
20. Substance P in the descending cholinergic projection to REM sleep‐induction regions of the rat pontine reticular formation: anatomical and electrophysiological analysesEuropean Journal of Neuroscience · 2002